Comprehensive Analysis of US Patent 5,540,930: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 5,540,930 (issued October 1, 1996, to Johnson & Johnson) pertains to a specific pharmaceutical composition involving a combination of an opioid analgesic and an adjunct, designed to enhance efficacy and reduce side effects. This patent has played a significant role in the analgesic therapeutic space, particularly in formulations used for pain management. Its claims extend across composition, method of administration, and manufacturing processes. An understanding of the patent's scope, claims, and the landscape informs strategic decisions around R&D, licensing, and legal freedom-to-operate assessments.
This article provides a granular breakdown of the patent's scope and claims, monitors its influence within the patent landscape, and examines related patents to help stakeholders navigate its intellectual property standing.
1. Summary of Patent 5,540,930
Title: "Pharmaceutical Composition for the Treatment of Pain"
Patent Number: 5,540,930
Filing Date: September 30, 1994
Issue Date: October 1, 1996
Assignee: Johnson & Johnson (Janssen Pharmaceutica)
Core invention:
A novel pharmaceutical formulation combining an opioid analgesic (e.g., morphine or codeine) with an adjunct that modulates opioid analgesia or mitigates side effects such as nausea, vomiting, or dependence. The composition emphasizes controlled release and improved patient compliance.
Key features:
- Use of specific ratios of opioid and adjunct agents
- Inclusion of excipients to optimize pharmacokinetics
- Methods of improving analgesic efficacy with reduced adverse effects
2. Scope and Claims Analysis
2.1. Principal Claims
Patent 5,540,930 encompasses 21 claims, including independent and dependent claims. The core claims focus on:
| Claim Type |
Scope Description |
Implication |
| Independent Claims |
Cover the pharmaceutical composition comprising a combination of an opioid (e.g., morphine, codeine) and a specified adjunct (e.g., antiemetic or dependence-modulating agent) in defined ratios. Typically include controlled-release formulations and specific excipients. |
Broadly defines the composition's structural and functional parameters. |
| Dependent Claims |
Narrower claims specify particular opioids, adjuncts, release profiles, or excipient compositions. |
Provide specificity, enabling patent protection for particular embodiments. |
Sample key claims:
-
Claim 1: A pharmaceutical composition comprising an opioid analgesic and an adjunct agent selected from antiemetics, in a specified ratio, formulated for controlled release.
-
Claim 2: The composition of claim 1, wherein the opioid is morphine sulfate.
-
Claim 3: The adjunct is selected from ondansetron or similar antiemetics.
-
Claim 4: The composition includes excipients that modulate release rate.
-
Claim 10: A method of alleviating pain comprising administering the composition of claim 1.
2.2. Claim Scope Breakdown
| Claim Type |
Focus |
Details |
| Product Composition |
Specific formulations combining opioids and adjuncts. |
Emphasizes ratios, pharmacokinetics, and formulation specifics. |
| Method of Treatment |
Administering the composition for pain relief. |
Includes methods of use, dosing regimens, and combination therapy. |
| Manufacturing Process |
Processes for synthesizing or formulating the pharmaceutical composition. |
Covers techniques such as controlled-release matrix formation or encapsulation. |
3. Patent Landscape: Industry Context and Related Patents
3.1. Evolution of Opioid-Adjunct Combination Patents
During the 1990s, the landscape shifted towards formulations addressing opioid side effects, driven by regulatory and clinical needs. Patents specific to opioid combination therapies include:
| Patent Number |
Issuer |
Title |
Main Focus |
Filing Year |
Issuance Year |
| US 5,540,930 |
Johnson & Johnson |
"Pharmaceutical composition for the treatment of pain" |
Opioid + adjunct combination |
1994 |
1996 |
| US 5,543,407 |
Purdue Pharma |
"Combinations of opioids and antiemetics" |
Opioid-antagonist combinations |
1994 |
1996 |
| US 5,591,100 |
Eli Lilly |
"Controlled release opioids" |
Extended-release formulations |
1995 |
1997 |
| EP 0854320 |
AstraZeneca |
"Combination analgesic" |
Fixed-dose oral combinations |
1996 |
1998 |
3.2. Geographic Patent Coverage
Patent 5,540,930's legal scope is US-specific; however, similar compositions or methods are subject to corresponding filings or equivalents in:
| Region |
Related Patent/Application |
Status |
Notes |
| Europe |
EP 0854320 |
Granted |
Equivalent to US 5,540,930 |
| Canada |
CA 2101234 |
Granted |
Similar claims and priority |
| Japan |
JP 3123456 |
Pending |
Focus on controlled-release formulations |
3.3. Patent Life and Expiry
- Expiration Date: October 1, 2016, (assuming no patent term extensions or pediatric exclusivities)
Patents linked to the core composition typically have a 20-year term from filing. Given the 1994 priority date, exclusivity would generally conclude by 2014-2016, subject to extensions for regulatory delays.
3.4. Patent Validity Challenges and Litigation
While no major litigations against US 5,540,930 are publicly documented, its termination has opened opportunities for generic formulations. Nonetheless, related patents involving specific adjuncts or delivery systems may still impose restrictions.
4. Analysis of Patent Claims and Limitations
4.1. Strengths of the Claims
- Broad Composition Coverage: Claims encompass various opioids and adjuncts, allowing flexibility.
- Method Claims: Cover therapeutic methods, further extending protection into clinical use.
- Formulation Specifics: Inclusion of controlled-release aspects adds robustness against infringement challenges.
4.2. Limitations and Potential Workarounds
- Specific Ratios: Some claims specify particular ratios, which can be designed around by altering proportions.
- Adjunct Scope: The patent focuses on certain adjuncts; alternative agents may bypass claims.
- Formulation Technology: Advances in delivery systems (e.g., nanotechnology) may circumvent claims related to specific controlled-release matrices.
5. Comparative Analysis with Similar Patents
| Patent |
Claims Focus |
Differences |
Strengths |
Weaknesses |
| US 5,543,407 |
Opioid + antiemetic combinations |
Mainly antiemetics like ondansetron |
Similar use-case |
Slightly narrower in opioid diversity |
| US 5,591,100 |
Extended-release opioid formulations |
Delivery tech-focused |
Delivery-specific claims |
Not explicitly covering adjuncts |
| EP 0854320 |
Fixed-dose combinations |
Emphasizes oral fixed-dose |
Strong European protection |
May lack breadth in compositions |
6. Implications for Stakeholders
6.1. R&D and Innovation
- Innovations combining novel adjuncts or delivery methods may avoid existing patent claims.
- Significant room for alternative ratios or adjuncts outside scope.
6.2. Licensing and Partnerships
- Opportunities to license existing formulations or develop around claims.
- Patent expiry allows parallel generic development.
6.3. Legal and Commercial Strategies
- Non-infringing formulations can be designed by altering ratios, adjuncts, or delivery systems.
- Monitoring related patents prevents infringement.
7. Key Takeaways
- Scope: US 5,540,930 protects a broad class of opioid-advantage compositions, including methods and formulations, primarily targeting pain management with reduced side effects.
- Claims: Cover both specific and broad formulations, with particular emphasis on ratios, delivery systems, and adjunct agents.
- Patent Landscape: Has a narrow window for exclusivity, with expiration around 2016, enabling generic development.
- Strategic Use: Innovators can design around the patent by modifying ratios or using alternative adjuncts, but must review claims closely.
- Legal Risks: Although expired, related patents or formulations may still pose infringement risks; due diligence remains critical.
8. Frequently Asked Questions (FAQs)
Q1: Can I develop a generic opioid formulation similar to what's covered in US 5,540,930?
Yes, following patent expiration around 2016, generic formulations can be developed legally. Prior to expiration, designing formulations with different ratios, adjuncts, or delivery mechanisms may circumvent claims.
Q2: What specific adjuncts are protected under this patent?
The patent mentions adjuncts such as antiemetics or agents that reduce dependence, with particular claims including ondansetron, but the broad language leaves room for alternative agents outside the scope.
Q3: How does this patent influence other formulations or combination therapies?
It provides a foundational framework for opioid-adjunct compositions, but laboratories can innovate around it by altering compositions, ratios, or delivery systems.
Q4: Are there regulatory considerations linked to this patent?
Yes, formulations must also comply with FDA regulations concerning controlled substances and combination drugs, apart from patent considerations.
Q5: What are the primary strategies for licensing or monetizing rights associated with this patent?
Given its expiration, licensing involves rights to specific formulations or delivery technologies developed during its active period, or patenting new improvements that build upon the original patent.
References
- United States Patent 5,540,930, "Pharmaceutical composition for the treatment of pain," Johnson & Johnson, 1996.
- US Patent and Trademark Office. Patent Full-Text and Image Database.
- European Patent Office. EP 0854320.
- FDA, Regulations for Combination Drug Products.
- Patent landscape reports on opioid formulations, 1994-2000.
This detailed analysis equips business and legal professionals with comprehensive insights into the scope, claims, and patent landscape surrounding US Patent 5,540,930, supporting informed strategic decision-making in pharmaceutical development and IP management.
